At Battersea Hospital we Understand the Side Effects of GLP1 and GIP Therapies
GLP1 (glucagon-like peptide1) and dual GLP1/GIP therapies such as semaglutide (Ozempic) and tirzepatide (Mounjaro) have transformed modern weight management. Their ability to regulate appetite, improve metabolic health, and drive significant weight loss has made them increasingly popular in both NHS and private settings. However, as with any medical treatment, it is essential to understand the potential side effects and to approach therapy under proper clinical supervision.
Common Side Effects: Gastrointestinal Symptoms
The most frequently reported side effects of GLP1 and GIP medications are
gastrointestinal (GI) in nature. These include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Reduced appetite
Clinical studies consistently show that these symptoms affect a significant proportion of patients. Evidence suggests that
40-50% of individuals experience GI symptoms, particularly during the early stages of treatment or dose escalation, although both Ozempic and Mounjaro have roughly the same amount of symptoms. These effects are usually mild to moderate and tend to improve over time as the body adapts.
This is why doctor-led programmes carefully titrate dosing over time, allowing the body to adjust and minimising discomfort. Without proper supervision, rapid dose increases can significantly worsen tolerability.
Less Common but Important Risks
While most side effects are manageable, there are
less common but clinically significant risks to be aware of:
- Gallbladder disease (e.g. gallstones)
- Delayed gastric emptying (gastroparesis)
- Bowel obstruction (rare)
- Pancreatitis (rare but serious)
These events are well known but thankfully rare.
Importantly, broader reviews suggest that while early trials raised concerns about pancreatitis risk, more recent large analyses do not confirm a clear class-wide increase in risk, highlighting the importance of individual assessment and monitoring.
Emerging Considerations
As these medications become more widely used, researchers are continuing to explore long-term and emerging effects. Some studies suggest potential concerns such as:
- Loss of lean muscle mass during rapid weight loss
- Possible effects on bone density
- The need for ongoing therapy to maintain results
A recent clinical review highlights that although gastrointestinal symptoms dominate, long-term safety and adherence remain areas of active research.
The Importance of a Doctor-Led Approach
At Battersea Hospital, we emphasise that GLP’1 and GIP therapies are not standalone solutions. They must be delivered within a holistic, medically supervised programme that includes:
- Careful patient selection
- Gradual dose titration
- Nutritional and lifestyle support
- Ongoing monitoring for side effects
This approach ensures that benefits are maximised while risks are minimised.
A Balanced Perspective
GLP1 and GIP-based treatments represent a powerful advancement in weight management. For many patients, the benefits can be life-changing. However, understanding potential side effects and managing them appropriately is key to safe and effective outcomes.
With the right clinical guidance, these therapies can be used as part of a sustainable, evidence-based strategy for long-term health improvement.